Meds & supplements › Brexucabtagene autoleucel
Medicine
TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, and SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS. Do not administer TECARTUS to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids. Neurologic toxicities, including life-threatening reactions, occurred in patients receiving TECARTUS, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with TECARTUS. Provide supportive care and/or corticosteroids, as needed. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, AND SECONDARY HEMATOLOGICAL MALIGNANCIES See full prescribing information for complete boxed warning. Cytokine Release Syndrome (CRS), including life-threatening reactions, occurred in patients receiving TECARTUS.
TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
1.2 Acute Lymphoblastic Leukemia TECARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
TECARTUS may cause side effects that are life-threatening and can lead to death. Call or see your healthcare provider or get emergency help right away if you get any of the following: Fever (100.4°F/38°C or higher) Difficulty breathing Chills or shaking chills Confusion Dizziness or lightheadedness Severe nausea, vomiting, or diarrhea Fast or irregular heartbeat Severe fatigue or weakness It is important to tell your healthcare provider that you received TECARTUS.
Your healthcare provider may give you other medicines to treat your side effects. What is TECARTUS? TECARTUS is a treatment for adults with mantle cell lymphoma or acute lymphoblastic leukemia. It is used following disease progression while on or after other treatment. TECARTUS is different than other cancer medicines because it is made from your own white blood cells, which have been modified to recognize and attack your lymphoma cells.
Before getting TECARTUS, tell your healthcare provider about all your medical problems, including if you have or have had: Neurologic problems (such as seizures, stroke, or memory loss) Lung or breathing problems Heart problems Liver problems Kidney problems A recent or active infection Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive TECARTUS? Since TECARTUS is made from your own white blood cells, your blood will be collected by a process called "leukapheresis" (loo-kah-fur-ee-sis), which will concentrate your white blood cells. Your blood cells will be sent to a manufacturing center to make your TECARTUS. Before you get TECARTUS, you will get 3 days of chemotherapy to prepare your body.
When your TECARTUS is ready, your healthcare provider will give it to you through a catheter placed into your vein (intravenous infusion). The infusion usually takes less than 30 minutes. You will be monitored daily for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 2 weeks after getting TECARTUS.
Your healthcare provider will help you with any side effects that may occur. You may be hospitalized for side effects. Your healthcare provider will discharge you if your side effects are under control and it is safe for you to leave the hospital. Your healthcare provider will want to do blood tests to follow your progress.
It is important that you do have your blood tested. If you miss an appointment, call your healthcare provider as soon as possible to reschedule.
Avoid driving for at least 2 weeks after you get TECARTUS. Do not donate blood, organs, tissues, or cells for transplantation. What are the possible or reasonably likely side effects of TECARTUS? The most common side effects of TECARTUS include: Fever (100.4°F/38°C or higher) Low white blood cells (can occur with a fever) Low red blood cells Low blood pressure (dizziness or lightheadedness, headache, feeling tired, short of breath) Fast heartbeat Confusion Difficulty speaking or slurred speech Nausea Diarrhea TECARTUS may increase your risk of getting cancers including certain types of blood cancers.
Your healthcare provider should monitor you for this. These are not all the possible side effects of TECARTUS. Call your healthcare provider about any side effects that concern you. You may report side effects to the FDA at 1-800-FDA-1088.
sofidex [Internet]. Daloreum; c2026. Brexucabtagene autoleucel; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/brexucabtagene-autoleucel
sofidex. (2026, August 2). Brexucabtagene autoleucel. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/brexucabtagene-autoleucel
Brexucabtagene autoleucel. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/brexucabtagene-autoleucel
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.